Recently, inhibitors targeting the KRAS G12D mutation have also transitioned from being “undruggable” to becoming “druggable.” Hence, we extended our findings to KRAS G12D–mutant pancreatic cancer cells. The gene discussed is KRAS; the disease is familial pancreatic carcinoma.